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Abstract
Cheap and massively parallel methods to assess the DNA-binding specificity of transcription factors are actively sought,
given their prominent regulatory role in cellular processes and diseases. Here we evaluated the use of protein-binding
microarrays (PBM) to probe the association of the tumor suppressor AP2a with 6000 human genomic DNA regulatory
sequences. We show that the PBM provides accurate relative binding affinities when compared to quantitative surface
plasmon resonance assays. A PBM-based study of human healthy and breast tumor tissue extracts allowed the identification
of previously unknown AP2a target genes and it revealed genes whose direct or indirect interactions with AP2a are affected
in the diseased tissues. AP2a binding and regulation was confirmed experimentally in human carcinoma cells for novel
target genes involved in tumor progression and resistance to chemotherapeutics, providing a molecular interpretation of
AP2a role in cancer chemoresistance. Overall, we conclude that this approach provides quantitative and accurate assays of
the specificity and activity of tumor suppressor and oncogenic proteins in clinical samples, interfacing genomic and
proteomic assays.
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Introduction
Since the complete sequencing of the human genome in 2001
[1,2], a wealth of DNA sequences has been available via online
databases [1,3,4,5,6,7]. The vast majority of the sequences are
intergenic or intronic, which may provide the platform for the
concerted action of DNA-binding regulatory proteins and
chromatin constituents. Knowledge of the integration of the
multitude of specific transcription factor binding may lay the
foundation for a system-wide understanding of fundamental
multicellular processes like development and growth, and for
more comprehensive descriptions of diseases that are linked to
gene expression misregulation. Human diseases like cancer have
often been linked to the improper interplay of proteins involved in
the transcriptional control of cells and tissues, as illustrated by the
prominent role of oncogenes in regulating gene transcription and
chromatin structure [8,9].
Several laboratory techniques have been devised for large scale
identification of transcription factor target sites, either in vitro or
using cellular assays [10]. One such assay relies on protein-
binding microarrays (PBM) that bear immobilized double-
stranded DNA molecules to which the binding of regulatory
proteins can be probed. PBMs have been prominently used for
the assignment of the binding specificities of purified transcription
factors [10,11,12,13,14,15]. A Recent studies also demonstrated
that PBMs can be used to assess the DNA-binding specificity of
transcription factors from cell extracts [10,16]. Subsequent
computational analysis of PBM-generated data allows the
computing of protein-specific DNA-binding weight matrices,
which can be used to scan genomic sequences to identify new
putative binding sites and transcriptional pathways, as exempli-
fied by those formed by the Hox proteins and developmentally
regulated genes [17]. However, the actual binding of the
transcription factors to the predicted site must be confirmed
experimentally, as it may be occluded by chromatin or DNA
modification or by other proteins binding overlapping DNA
sequences, while synergistic binding may occur on non-canonical
sites that are not detected by in silico predictions.
Activating protein 2 alpha (AP2a) is a transcription factor whose
binding sites were first discovered in cellular and viral cis-
regulatory sequences and gene promoters [17,18,19]. It belongs
to the TFAP2 family of sequence-specific DNA-binding polypep-
tides that share a highly conserved basic helix–span–helix DNA-
binding and dimerization domain at their C-terminus, and a less
conserved N-terminal proline-rich and glutamine-rich transcrip-
tional regulatory domain. The various TFAP2 isoforms, namely
AP-2a, AP-2b, AP-2c, AP-2d, and AP-2e in humans and rodents,
form homo and heterodimers that recognize GC-rich palindromic
DNA sequences related to the 59-GCCN3–4GGC-39 consensus
sequence [20,21].
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AP2a biological function stretches from the regulation of neural
crest formation during mice development to a proposed role in the
mitochondrial pathways leading to apoptosis [22,23,24]. Cloning
of AP2a coding sequence has allowed the identification of protein-
interaction partners and of a small set of potential target genes
[25,26,27,28]. Interestingly, AP2a DNA-binding specificity was
reported to be modulated by synergistic or antagonistic interac-
tions with other DNA binding proteins present in human tumor
cells, and changes in these interactions was associated to tumor
progression [21,24,29]. At present, a system-wide identification of
its direct and indirect target genes is not available, despite growing
interest raised by its action as a tumor suppressor or oncogene and
its implication in cancer progression and resistance to therapeutics.
PBMs have so far been used mostly to assess interactions to
short synthetic DNA sequences, for the modeling of the DNA
sequence specificity of transcription factors. Here we show that
PBMs can be used to perform large-scale assays of the interaction
of regulatory proteins from crude cellular extracts with long
genomic fragments such as promoters and enhancers. Assay of
approximately 6000 human genomic sequences allowed an ab initio
assignment of the target gene specificity of the AP2a tumor
suppressor, as a purified protein as well as from healthy and cancer
breast tissues from patients. Several target genes were validated in
cell-based assays. The PBM-based approach may thus allow the
identification of previously unknown target genes of tumor
suppressors in cancer cells, and it provides novel markers of
cancer progression at the interface of proteomics and genomics.
Results
AP2a binding assay on 6000 human genomic sequences
We first aimed at identifying potential target genes of the AP2a
oncogene/tumor suppressor protein by assessing its binding to
double-stranded DNA sequences immobilized on a microarray.
We used a collection of human genomic DNA sequences that was
originally devised for ChIP-chip assays [30]. This microarray
contains approximately 6000 promoter and intergenic regulatory
human DNA sequences of approximately 1000 bp length on
average (hu6k microarray) that were labeled with the Cy5
fluorophore. Bacterially expressed and purified AP2a protein
was incubated with the microarray, and its binding to particular
sequences was assessed using Cy3-labeled fluorescent antibodies
and microarray scanning. Dye bias was removed by the Loess
normalization, and the data was normalized first within each slide
and then among three independent slides, to remove intra- or
inter-slide biases (see Materials and Methods section). The
distribution of the normalized binding values is shown in
Figure 1A (see Table S1 for the complete data set and statistical
analysis). A high reproducibility was observed between individual
assays, with the majority of the coefficient of variation (CV) values
under 5%, and most under 10%, for both the red (Cy5 DNA
labeling, Figure S1A) and the green (Cy3 protein labeling, Figure
S1B) channels.
As PBMs rely on immobilized DNA molecules that reach high
local concentrations at the surface of microarrays, slow or
undetectable off-rates may occur [31]. Thus, whether a thermo-
dynamic binding equilibrium is reached during the assay, and
consequently whether accurate affinity values may be deduced
from PBM data has remained unclear. We addressed this issue by
assaying a set of dsDNA molecules chosen to have a wide range of
affinities, as predicted using a previously described AP2a hidden
Markov model of AP2-binding specificity (Figure S2), and as
assessed experimentally [32]. The DNAs were immobilized on
Biacore sensor chips using an oriented biotin-streptavin crosslink,
and the binding constants of purified AP2a were determined by
surface plasmon resonance (SPR) for low (E18), medium (E25,
E33) and high affinity (E38 and E58) DNA sequences. In parallel,
these sequences were also spotted on a small scale PBM, and AP2a
binding was assessed as described above. Affinity values deter-
mined by SPR were found to correspond well to the PBM-based
and weight-matrix-estimated affinities of AP2a, with a coefficient
of correlation of 91% (Figure 1B and Figure S3).
AP2a target genes network analysis
After validating the PBM-based interactions in vitro, we assessed
globally the functional significance of potential AP2a target genes.
A statistical analysis yielded 282 DNA sequences that were
significantly bound by AP2a (see Table S1 for a complete data set).
In order to assess if some of these hits may correspond to
previously identified AP2a targets, we compared the 282 PBM
sequences with AP2a target genes as listed on the TRANSFAC
Figure 1. Analysis of AP2a binding to PBM DNA sequences. (A)
Distribution of the measured values on each slide (red and green
channel) after normalization. Values on the X axis represent the log2 of
green or red fluorescences. Following value normalization, tracings
obtained from the two channels are superimposed. (B) Association of
protein-binding microarrays (PBM) and SPR-estimated binding affinities.
Five different sequences of 252 bp length were analyzed for AP2a
binding using PBM and SPR. The resulting relative affinity measurement
averages of 3 independent assays each were fitted by a linear
regression.
doi:10.1371/journal.pone.0022895.g001
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database (http://www.biobase-international.com). 49 genes rep-
resented on the hu6k microarray were also listed in the
TRANSFAC dataset. Among these 49 sequences, 6 were directly
bound by the recombinant AP2a protein on the PBM (Figure 2).
This first comparison indicated that the analysis of the binding of
recombinant AP2a to the PBM sequences can reveal functionally
relevant target genes. The biological significance of these 282
AP2a-bound sequences was assessed using the Ingenuity Pathway
Analysis software, among which 175 sequences could be associated
with one or several biological functions or diseases. Target genes
associated with cancer and hematological diseases featured
prominently (Figure 3A). A similar analysis of functions pertaining
to physiological systems and biological functions revealed an
enrichment of genes associated with development, cellular growth
and proliferation, or cell death (Figure 3B).
Network analysis was also performed to provide a graphical
representation of the biological inter-relationships of AP2a-bound
genes. This led to the identification of twenty-one networks whose
gene nodes preferentially associate with AP2a (Table S2). Among
the five most significant networks, three of them feature cancer
and/or development prominently. One represents the interaction
of cell-to-cell signaling intermediates with regulators of the cell
cycle and of embryonic development (Figure 4A). Another
network features the interactions of cell death regulators with
cancer, while the third one illustrates the connection of cancer-
linked proteins with the cell cycle and embryonic development
(Figure 4B and 4C). Other networks whose gene nodes are often
bound by AP2a were linked with developmental disorders and
cellular development and morphology (Figure S4). Overall, we
conclude that AP2a associates preferentially with developmental
regulator and cancer-associated genes. Taken together, these
analyses strongly supports the role of AP2a in developmental
regulation, as illustrated by the severe dysmorphogenesis of
numerous tissues and organs observed in AP2a-defficient mice,
as well as its role as a tumor suppressor or as an oncogene [20,21].
Cell-based validation of potential AP2a target DNA
sequences
Several promoters were selected for experimental validation
from the PBM and in silico-identified potential AP2a targets. This
was performed on the intergenic sequence of the Growth arrest-
specific protein 2 (GAS2) gene, an activator of p53-mediated
apoptosis [33,34], as well as the kallikrein 5 (KLK-5) gene, a
secreted protease involved in cancer progression [35,36,37,38].
The promoter sequence of the parvalbumine gene (OCM gene)
was selected as a negative control, on the basis of its low
interaction with AP2a on the PBM [39,40]. These sequences were
inserted upstream of a minimal promoter and the eGFP sequence
(Table S3), and they were transiently transfected into SW480
colon cancer cell line, as these cells display low endogenous AP2a
levels [41]. The OCM promoter sequence mediated a low level of
eGFP expression that was not affected by the co-transfection of an
AP2a expression vector, consistently with the lack of significant
interaction with the transcription factor in the PBM analysis
(Figure 5A). The intergenic GAS2 regulatory sequence increased
eGFP expression from the minimal promoter by approximately 8-
fold in the absence of AP2a, but this effect was abbrogated by the
expression of AP2a. The KLK-5 sequence mediated a low
expression comparable to that conferred by the OCM sequence,
and AP2a expression mediated a small but nevetherless significant
activation, in agreement with the occurrence of a AP2a binding
site. Similar results were obtained from similar experiments
performed using a hepatocarcinoma cell line (Figure S5). We
concluded that the novel AP2a target genes likely represent
functional interactions, in that AP2a expression could mediate
either a repressive (GAS2) or activating (KLK5) effect on these
target promoters.
Next, we assessed whether these AP2a interactions may take
place in the cell in the context of chromatin. AP2a binding sites
having the highest score computed from the weight matrix
prediction algorithm were localized on the DNA sequences
imobilized on the PBM, and the corresponding genomic sequences
were assayed for AP2a–interaction by chromatin immunoprecip-
itation-quantitative PCR (ChIP-qPCR) using a colon cancer cell
line that constitutively expresses this transcription factor [41].
AP2a was indeed found to interact with the predicted sites on the
GAS2 and on KLK-5 upstream regulatory sequences in the cancer
cells as well as to the AP2a binding site in the promoter of the
estrogene receptor gene used as a positive control (ESR1,
Figure 5B). RNA polymerase II was found to bind to the KLK-
Figure 2. Venn diagrams depicting the overlap between the sequences most potently bound by AP2a from different sources. (A) The
282 sequences found to be significantly bound by recombinant AP2a on hu6k PBM were compared to 1017 sequences bound by AP2a from healthy
breast tissues and 1925 sequences from breast cancer tissues. (B) The 282 sequences significantly bound by recombinant AP2a were compared to 48
sequences bound by AP2a from the TRANSFAC database and to the 149 sequences differentially bound by AP2a when comparing healthy to cancer
breast tissues. The comparison is as in panel A, except that the datasets obtained from tissue extracts were obtained using a significance cut-off of
p,0.01.
doi:10.1371/journal.pone.0022895.g002
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5 promoter but not to that of GAS2, as expected from the
activating and repressive role of AP2a seen in transfection studies,
respectively. This indicated that the PBM and in silico analysis
allowed the identification of functionally relevant target genes.
Association of AP2a from cancer tissue to human
genomic sequences
It has been proposed that AP2a DNA-binding specificity is
modulated by synergistic or antagonistic interactions with other
DNA binding proteins present in human tumor cells, and that
changes in these interactions may lead to tumor progression
[21,24,29]. AP2a association was therefore also assessed on the
6000 human genomic regulatory sequences in conditions where
these competitive or synergistic interactions may take place. Nuclear
extracts were generated from 4 healthy breast tissues and 8 breast
cancer biopsies, and they were applied to hu6k microarrays to
specifically detect AP2a binding [32]. Using nuclear protein extracts
from normal or cancerous breast tissues, 1017 and 1925 sequences
were identified as potential AP2a targets (See Tables S4 and S5 for
complete datasets and statistical analysis).
Among the 998 target sequences obtained from both the healthy
breast tissue and the breast cancer protein extracts using the log
fold change (protein/DNA) as endpoint, 53 also associated with
the purified protein (Figure 2A). These likely corresponds to direct
binding targets of AP2a as exemplified by chorionic gonadotropin
alpha promoter (CGA), which is a well characterized functional
and binding target of AP2a in tumor cells [42]. The synergistic or
antagonistic binding of AP2a with numerous other DNA-binding
proteins may explain different gene occurrence in the various
datasets. For instance, interactions observed from nuclear extracts
of healthy and/or cancerous tissues, but not from purified AP2a
may result from its ability to piggy-back other DNA-binding
proteins such as YY1, Sp1 or p53 [43,44,45].
Using a position weight matrix (PWM) prediction algorithm for
AP2a binding sites [32], we tested the 50 sequences most
prominently bound by AP2 from the PBM data sets generated
with recombinant AP2a and with the normal and tumor tissue
extracts. We found that the occurrence of AP2a predicted binding
sites was 1.5 fold lower in sequences obtained using normal tissue
extracts as compared to those obtained with the recombinant
Figure 3. Functional analysis of AP2a target genes. Most prominent functional categories of diseases and pathological disorders (A), or of
biological functions (B), associated with 272 potential AP2atarget genes (PBM binding values, p,0.05). The threshold significance line indicates a
value of 2log(p-value) greater than 1.25.
doi:10.1371/journal.pone.0022895.g003
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AP2a (Table S6). This result thus supports the interpretation of an
indirect binding of AP2a occurring from tissues extract and the
proposed ability of AP2a to interact with other proteins to bind its
target genes in the context of normal cells. Interestingly, there was
a higher percentage of genes with a predicted AP2a binding sites
when analyzing the dataset obtained with the cancer extracts
(Table S6). This likely reflects a greater ability of AP2a to bind
DNA directly in cancer cells as compared to normal cells, as also
indicated by the high number of targets commons to recombinant
AP2a and to the cancer extracts (Figure 2A). Thus, oncogenic
transformation may be accompanied by the release of AP-2 from
interactions with proteins that hinder its ability to directly interact
with its cognate recognition sequence. Indeed, a higher number of
sequences significantly bound by AP2 were obtained from the
cancer extract relative to the healthy tissue (Figure 2A). When
similarly using a PWM algorithm that predict p53 binding sites
Figure 4. Network diagrams illustrating prominent regulatory relationships among AP2a-bound genes. Grey-filled shapes represent
genes significantly bound by recombinant AP2a on the PBM. Main functions related as these networks, as constructed and classified by the Ingenuity
Analysis Software are cellular development, cell-to-cell signaling and interaction, and embryonic development (A), cell death, cancer and genetic
disorder (B), or cancer, cell cycle and embryonic development (C).
doi:10.1371/journal.pone.0022895.g004
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(p53mh, [46]), little difference was found between hits obtained
from the cancer and normal tissue extracts (Table S6). However,
when genes that have a low PWM score for AP2a binding and a
high score for p53 binding were extracted from these datasets, as
genes that AP2a might indirectly bind by piggybacking p53, a
higher proportion was bound by AP-2 from the normal tissue
extracts. This implied that such genes may bind the transcription
factor indirectly, via AP-2’s ability to associate with p53, but that
this ability may be lost or decreased upon oncogenic transforma-
tion. Indeed, some of these genes are known regulatory targets of
p53, as exemplified by the REPRIMO, GDF9 and TLR3 genes
[47,48,49]. Two other such genes encode the matrix metallopro-
teinase 2 (MMP2) and Rad51, where AP2a DNA binding and
regulation was shown experimentally to require p53. Consistently,
these genes were not recognized by purified AP2a recombinant
protein but interaction was only observed when using nuclear
extract (Tables S1, S4, S5). Thus, the PBM results suggest that
indirect interactions of AP2a are much more widespread than
previously known and that oncogenic transformation is accompa-
nied by a change in AP2a target gene specificity mediated in part
by the modulation of these indirect interactions. In this respect,
novel AP2-bound genes from cellular datasets feature prominent
cell cycle-related regulatory targets of the p53 and Rb tumor
suppressors such as the E2F and cyclin gene families [50].
Comparison of AP2 binding specificity from normal and tumor
tissues yielded generally correlated results, as many genes that
were bound by AP2a in the healthy tissue extract were also bound
using tumor extracts (Figure 2A). The higher number of genes
bound from the tumor extracts can be attributed to the combined
effects of differences in the activity of AP2a and of the proteins it
synergizes or antagonizes with. Consistently, cancer-associated
genes that had not been previously associated to AP-2 were
identified in the tumor extracts datasets, as for instance the breast
cancer susceptibility gene 2 (BRCA2) and the cyclin-dependent
kinase 2 gene. Comparison of the binding strength of regulatory
sequences detected using the two types of extract yielded 149
sequences that were differentially bound by AP2a (Figure 2B and
Figure 6A). When a similar comparison was performed between 2
sets of 4 randomly selected breast cancer extracts, to assess the
experimental noise, 52 differentially bound sequences were
obtained (Figure 6B). Differences between the two sets of tumors
may reflect the known heterogeneity of breast tumors [21].
Nevertheless, the nearly three-fold higher number of differentially
bound genes from healthy versus breast tumors tissue comparisons
indicated that AP2a specificity differs much more between normal
and cancerous tissues than among individual tumor types. One of
the genes bound solely from the cancer biopsy extract was found to
encode Bcl2, which is known to be down-regulated by AP2a to
provoke tumor cell apoptosis upon chemotherapy [23]. Functional
analysis of networks associated with genes differentially bound by
AP2a in normal and tumor extracts showed that genes are
involved in genetic disorders and cancer, but also in reproductive
system disease (Table S7). Taken together, these results imply that
the PBM-based approach may be used to detect bona fide direct
and indirect targets of AP2 as well as reveal novel ones, and that it
may differentiate healthy from cancerous breast tissues. They also
support previous proposals that AP2a DNA binding may be
subjected to antagonistic or synergistic interactions with numerous
other nuclear proteins in tumor cells [21,51,52].
Discussion
In this study, we evaluated whether double-stranded DNA
fragments bearing whole promoters and regulatory sequences and
immobilized on a PBM may be used to identify the target genes of
an oncogenic transcription factor. We found that binding values
obtained from the PBM correlated well with the affinities
Figure 5. Functional validation of AP2a binding sites selected
from PBM and weight matrix-based predictions. A) Genomic
sequences corresponding to the OCM and GAS2 genes were selected
on the basis of low and high binding potential, respectively, from the
PBM dataset, while the KLK5 sequence was selected as an AP2a-bound
promoter by weight matrix-based predictions with a score of 39
(medium affinity). SW480 cells were transiently co-transfected with
reporter constructs containing these ,900 bp regulatory sequences
genomic sequences inserted upstream of a minimal promoter and eGFP
sequence, and with either an AP2a expression vector or with the
corresponding empty control vector. eGFP fluorescence was quantified
by cytofluorometry. Graphs show the fold change of eGFP expression in
absence or presence of AP2a as normalized to the fluorescence level
obtained from the cotransfection of the eGFP reporter plasmids alone
(n = 4, ***: p,0.001, **: p,0.005; two-tailed, two-sample equal variance
t-test). B) ChIP-qPCR analysis of in vivo AP2a binding was performed
using KM12C colon cancer cells that constitutively expresses AP2a [41].
The ,900 bp sequences used in the eGFP reporter assay of panel A
where searched for AP2a binding motifs utilizing the prediction weight
matrix shown in Fig. S2, and qPCR primers were designed for the
quantification of the assigned regions. A known AP2a binding site on
the Estrogen Receptor 1 gene (ESR1) promoter serves as positive
control, while an intergenic sequence upstream of the KLK5 gene was
used as negative control. The abundance of RNA polymerase II indicates
promoter occupancy by the transcriptional machinery. The initial
concentration ratio of IP sample to sample Input were calculated as
previously described [71]. Values obtained from the immunoprecipitat-
ed samples were multiplied by a factor of 100 before plotting.
doi:10.1371/journal.pone.0022895.g005
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determined by surface plasmon resonance or computed with a
weight matrix. This indicated that PBMs provide reliable
estimations of the binding strength. Genomic fragments that bind
AP2a on the PBM and/or in silico were found to mediate AP2a-
regulated expression in transfection assays. Occupancy of the
AP2a binding sites within the native chromatin structure of tumor
cell lines was confirmed experimentally. This also indicated that
valid target genes may be identified by combining these PBM and
modeling approaches. Thus, the increase in non-specific back-
ground binding to the long DNA molecules, as resulting from the
use of relatively long promoter and enhancer sequences, did not
mask sequence-specific functional interactions.
In vivo, an additional level of complexity arises from the
chromatin structure, which may shield the DNA from protein
binding. Thus, a high binding potential in vitro or in silico cannot
provide definitive evidence that a putative binding site will be
occupied in any given cell type. Furthermore, binding may be
occluded by other transcription factors that interact with
overlapping sites on the promoter, or conversely, protein
association may allow interactions to non-canonical sites. The
relative contributions of chromatin and of other transcription
factors to the actual binding site occupancy in vivo remains difficult
to assess for eukaryotic transcription factors, as large-scale assays of
promoter binding occupancy with chromatin alone, or with
competing or synergizing transcription factors but without
chromatin, have not been available.
The finding that the most prominent functional feature of AP2a
target genes relates to cancer was validated experimentally for two
newly identified AP2a target genes. Kallikrein 5 is a member of
the kallikrein family of extracellular proteases that includes the
prostate-specific antigen, and it is currently emerging as some of
the most prominent biomarkers of tumor progression for various
types of cancers [53,54,55]. The growth-arrest specific 2 (GAS2)
protein modulates cell susceptibility to p53-dependent apoptosis
upon chemotherapy [33,34]. The finding of an AP2a-mediated
regulation of both genes may thus provide a molecular mechanism
for its proposed role in tumor progression and resistance to
chemotherapy.
Interestingly, we found that promoter-binding by AP2a from
total cell nucleus extracts differs significantly from that observed
with the purified protein. Because nuclear extracts contain
regulatory proteins such as transcription factors but do not
mediate nucleosome deposition, differences in the binding patterns
obtained from healthy and cancer tissues imply that AP2a binding
is regulated by other regulatory proteins present in the extracts.
This finding correlates well with previous observations of the
synergistic or antagonistic interactions of AP2a with other
transcription factors and oncogenes such as p53, Rb and c-Myc
[21,51,52]. The recruitment of AP2a at p53-binding sites and the
resulting synergistic regulation of p53 target promoters has been
associated to the tumor suppressor effects of the two transcription
factors [21,51,52]. Interaction of AP2 from the crude extracts was
observed with two such AP2a and p53-regulated genes presented
on the PBM, those of the matrix metalloproteinase 2 and Rad51
genes [43,44,45], while these interactions were not seen with the
purified protein. In addition to the alterations of AP2 DNA
binding specificity by piggybacking effects, the formation of
heterodimers of AP2a with other AP2 species may also alter its
interaction with target genes. Although, the DNA binding
specificity of the various isoforms are generally considered to be
similar, the possibility of an altered interaction of particular
heteromultimers from the tissue extracts but not from the purified
AP2a cannot be excluded. For instance, a preferential interactions
of the AP2a/AP2c or AP2b/AP2c dimmers has been proposed to
occur on the KAI1 prostate cancer metastasis suppressor gene
[56]. Thus, numerous types of interactions may concur to
modulate the interaction of cellular AP2a with its target genes
and may correspondingly affect its interaction with the PBM.
Figure 6. PBM analysis of AP2a extracted from healthy or tumor tissue samples. (A) Result of a comparison between 4 normal samples and
4 cancer samples, in the form of an MA-plot. The X-axis (A values) shows the average of the log ratios (protein/DNA) of binding from normal and
cancer extracts to each target DNA sequence, and it thus displays the average AP2 binding value to each gene. The Y-axis (M values) represents the
averaged difference of log ratios (protein/DNA) between the normal and the cancer samples, and thus represent differential binding when
comparing healthy and diseased tissues. Potential differential binding was defined as an absolute value of M.1, as shown with dashed lines,
corresponding to a 2-fold difference between cancer and normal tissues. 149 genes were selected using this cut-off. Circles indicate statistically
significant differential binding. (B) Same data for a comparison between two sets of 4 randomly selected cancer samples; 52 genes were selected
using the same criteria as for panel (A).
doi:10.1371/journal.pone.0022895.g006
Microarray Analysis of AP2a Tumor Suppressor
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e22895
Overall, we conclude that the use of genomic DNA-bearing
PBMs and unfractionated cell nuclear extracts can provide so far
unavailable data allowing (i) to distinguish transcription factor
cooperative or antagonistic effects from those elicited by
chromatin, and (ii) to interpret some of the discrepancies noted
between cellular assays such as ChIP and assays of purified
components in vitro or from in silico predictions. PBMs can thus
complement other microarray-based assays of disease related
proteins, as may be needed to achieve more efficient integrated
molecular diagnostics of cancer.
Materials and Methods
Ethics statement
Written informed consent obtained from patients undergoing
tumor biopsies and the protocol for use of human tissue samples
were in accordance to the guidelines of -and approved by- the
ethical committee of the University Hospital of Lausanne
(Switzerland).
Tissues and cell lines
Five breast cancer frozen tissues were obtained from the Tissue
Bank of the University Hospital of Lausanne. Five normal breast
tissues from reduction surgeries were obtained from Dr. Brisken C.
Laboratory (ISREC, Lausanne). All tissue samples were histolog-
ically examined by a pathologist (H.A.L.).
SW480, humancolorectal adenocarcinoma hybridoma (ATTC
line number CCL-228), was cultured according to the supplier’s
instructions. This cell line is documented to express little or no
significant AP2 levels [22,23,24]. AP2a-expressing KM12C,
human colon cancer cell line [57], was grown in DMEM (ATCC
catalogue number 30-2002) supplemented with 10% FBS.
Preparation of proteins and DNA reagents
Full-length human TFAP2a protein was overexpressed as a
GST-fusion protein in Echerichia coli W3110 utilizing the previously
described expression vector pGEX-AP2 following the manufac-
turer’s instructions [32]. The GST-AP2a fusion protein was
purified by column affinity chromatography on Glutathione
Sepharose 4B (Amersham Biosciences). Glycerol was added to
the final concentration of 10%, and aliquots were shock frozen in
liquid nitrogen and stored at 280uC.
Plasmids bearing standard DNA sequences for AP2a binding
served as template for PCR-mediated DNA amplification [32].
Double stranded 252 bp sequences for biotin-streptavidin coupling
to biacore sensor chips or spotting on microarrays were amplified
by polymerase chain reaction (PCR) utilizing 59-biotin-CGA CGT
TGT AAA ACG ACG GC-39 and 59-TGA CCA TGA TTA
CGC CAA GC-39 primers, as described previously [32]. DNA
fragments were purified form 16TAE agarose gels (1.8% w/v)
utilizing the ‘PCR and Gel purification kit’ (Promega) and DNA
concentration was quantified with a Nanodrop ND-1000 spectro-
photometer (Witeg AG).
Preparation of total protein extracts from tissue samples
Tissue sample sections of 30 mm were thawed on ice in a
solution of 16 PBS (10 mM pH 7.4 Phosphate, 137 mM NaCl,
2.7 mM KCL) containing a cocktail of protease inhibitor (Roche
complete protease inhibitor cocktail tablets, Roche) followed by
centrifugation of the tissue fragments at 4uC for 5 min at
3500 rpm. Pellets were recovered into 250 mL Low Salt Lysis
Buffer (10 mM Tris pH 7.8, 1.5 mM MgCl2, 10 mM KCl) and
incubation allowed on ice for 15 min. Cells were lysed by addition
of 0.5 mL NP-40 [0.02% w/v] and mixed by vortexing for 5 s.
Nuclei were harvested by centrifugation for 5 min at 3500 rpm,
4uC and the pellet washed with 300 mL Low Salt Lysis Buffer.
After an additional centrifugation step (3500 rpm at 4uC for
5 min) the supernatant was taken off and the pelleted nuclei
resuspended in 25 mL of High Salt Lysis Buffer (10 mM Tris
pH 7.8, 1.5 mM MgCl2, 10 mM KCl, 400 mM NaCl, NP-40
[3% w/v]). Samples were mixed by vortexing for 5 s and
incubated on ice for 30 min with vortexing every 5–10 min in
order to allow extraction of nuclear proteins. The supernatant
containing the nuclear proteins was transferred into new coded
tubes and diluted by adding 25 mL of Low Salt Buffer to bring the
final NaCl concentration to 200 mM and immediately frozen in
liquid nitrogen.
Protein-binding microarray assay
Spotting of custom microarrays was done as described
previously [32]. In short, DNA concentrations were adjusted to
170 ng/mL unless stated otherwise and mixed 1:1 with 26spotting
buffer (66SSC; 3 M betaine). Each sequence was spotted 20 times
on different positions on the array slide. Spotting was carried out
with an ESI arrayer (BioRad) at 50–55% humidity and 23uC onto
Nexterion aldehyde slides (Schott).
Custom-made PBMs, or the hu6k microarrays containing
approximately 6000 human genomic sequences of similar length
(980 to 1000 bp; Aviva Systems Biology, San Diego, USA; [30])
were treated prior to use as follows: slides were washed twice for
2 min with 16TEN (40 mM Tris-HCL [pH 7,5], 1 mM EDTA,
150 mM NaCl), then reduction of aldehydes was performed in
the reduction solution (0.25% NaBH4 (w/v) in PBS 16/EtOH
25%) for 10 min, followed by two washes of 2 min with 16TEN.
Slides were then blocked in the blocking solution for 1 h (5%
skimmed milk in PBS 16, 0.05% Tween-20) followed by two final
washes for 2 min with 16TEN. The DNA on the arrays was end-
terminally labeled following the protocol described here: pre-
incubation of slides with 16PBS containing 100 mg/mL adeno-
sine monophosphate (AMP) was followed by application of the
DNA labeling mix (16NEB buffer 4, 100 mg/mL AMP, 0.1 mM
CoCL2, 0.2 mM ddNTP-Cyanine5 [Perkin Elmer], 0.02 U/mL
TdT [NEB]). After incubation for 1.5 h at 37uC in the absence of
light, slides were washed twice for 2 min in 16TEN and spun
dry.
AP2-binding reaction mix (2.5 mM Tris-Hcl pH 7.9, 15 mM
KCl, 1 mM MgCl2, 0.025 mM EDTA, 12.5 mg/ml BSA, 0.05%
NP40 2% [w/v] skimmed milk, 0.015 mg/mL poly-dIdC,
0.15 ng/mL purified GST-AP2a or 100 to 1000 ng/ml of total
proteins from nuclear cell extract) was applied onto each array
slide and incubated at room temperature (RT) in the absence of
light for 1 h, as described previously [14,32]. Slides were washed
563 min with 16 PBS supplemented with 1% (v/v) Tween 20,
365 min with 16 PBS containing 0.01% (v/v) Triton-X-100
and spun dry. Next, the primary antibody (AP2a (C-18):sc-184,
Santa Cruz Biotechnologies) was applied in 16 PBS supple-
mented with 2% skimmed milk, and incubated for 1 h at RT in
the absence of light. Slides were washed 365 min with 16 PBS
with 0.05% (v/v) Tween 20, 365 min with 16PBS with 0.01%
(v/v) Triton-X-100, before incubating with the secondary
antibody (Cy3-labeled Alexa Fluor 546 goat anti-rabbit IgG,
Molecular Probes) in 16 PBS supplemented with 2% (w/v)
skimmed milk for 1 h at RT in the absence of light. This was
followed by a final washing cycle (365 min with 16PBS, 0.05%
[v/v] Tween 20, 365 min with 16PBS, 0.01% [v/v] Triton-X-
100 and once for 5 min with 16PBS). Fluorescence was scanned
with an Agilent G2566AA scanner and analysed using the
GenePix Pro6 software.
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Functional analysis of PBM data sets
The GenePix data was analyzed using the R statistical software
[58] and the Limma Bioconductor package [59]. A Loess
normalization was performed on the data to normalize the data
within the same slide, assuming that the difference in fluorescence
between the DNA and protein channels is independent of the total
fluorescence, followed by quantile normalization of the inter-slide
variations. Limma was used to assess the genes that showed
differential binding when comparing log-ratios (log[protein/
DNA]).
Functional classification of AP2 target genes was performed on
the average of data from 3 independent PBM experiments using
the Ingenuity Pathways Analysis (IPA) software (see: www.
ingenuity.com).
78 genes previously experimentally assessed as AP2a target
genes were obtained by the addition of Transfac lists of genes
bound by TFAP2A and of genes regulated (directly or indirectly)
by TFAP2A, of which 45 were also represented on the PBM.
Potential AP2 binding sites on the immobilized sequences were
predicted using a previously described PWM (http://ccg.vital-it.
ch/httfs/software/ap2_pfsearch.html; [32]).
Quantification of protein-DNA interaction by surface
plasmon resonance
Measurements were carried out in a Biacore 3000 (GE
Healthcare) machine. Immobilization and binding experiments
were performed in HNM buffer (10 mM HEPES, pH 7.4,
150 mM NaCl, 5 mM MgCl2) at a flow rate of 5 ml/min unless
otherwise stated. Streptavidin was covalently coupled to the
surface of a sensor chip CM5 using standard amine coupling
procedure by injecting the reagents in the following order: 35 ml
0.05 M NHS/0.2 M EDC mixture, 50 ml streptavidin (300 mg/
ml) in 10 mM acetic acid (pH 4.5) and 35 ml 0.1 M ethanol-
amine. Finally 100 ml SDS 0.5% at 100 ml/min was injected to
remove unbound proteins. The amount of immobilized strepta-
vidin was approximately 3000 RU. Biotinylated DNA fragments
were diluted in HNM buffer (1–2 ng/ml) and injected over the
streptavidin-coated surface until desired amount was immobi-
lized (typically between 300 and 500 RU). Unbound DNA was
removed by injecting 100 ml SDS 0.5% at 100 ml/min. Different
concentrations of AP2a ranging from 0 to 400 nM were applied
in a random order to the surface for 10 minutes in order to reach
equilibrium. Surface regeneration was achieved with 100 ml SDS
0.5% at 100 ml/min to dissociate bound proteins. One channel
without DNA probes was used as reference in all experiments to
correct the binding response for bulk refractive index changes
and unspecific binding. Apparent affinity constants were
obtained by plotting the responses at equilibrium versus AP2a
concentration. BiaEvaluation Software Version 4.1 (Biacore) and
IGOR Pro Version 5.05A (Wavemetrics) were used for data
processing.
Reporter plasmids and transfection assays
The expression cassette, consisting of a minimal CMV promoter
and eGFP coding sequence as reported previously (pBSGFPmin,
[60]), was flanked by BamHI and XbaI restriction sites by PCR and
inserted into a pBSKSII backbone resulting in plasmid pJK6-
CMVmin-eGFP. Human genomic DNA sequences identified as
potential AP2a binding sites from assays with the hu6k arrays
(OCM and GAS2) and one sequence assigned as an AP2a target
by weight-matrix analysis (KLK-5) were inserted upstream on the
minimal CMV promoter of pJK6-CMVmin-eGFP, resulting in
three reporter plasmids (see Table S2). The DNA sequence feature
and biological function of human genes OCM [39,40], GAS2
[33,34,61,62,63] and KLK-5 [35,36,37,38,64,65,66,67,68,69,70]
were described elsewhere.
The effects of AP2a expression on the eGFP expression vectors
were studied by transient co-transfections of eGFP reporter
constructs previously described, and AP2a expressing vector
pSP72(RSV)AP2 or the empty pSP72(RSV)NN plasmid as control
[27]. Total amounts of DNA per transfection were adjusted with
pUC118 plasmid DNA. Transfections were performed using the
Fugene reagent (Roche) according to the manufacturer’s instruc-
tions. Four days after transfection, cells were detached utilizing
ESGRO Complete Enzyme-Free Dissociation Solution (Millipore)
and eGFP expression levels were recorded on a CyAn ADP
analyzer (Dako).
Chromatin Immunoprecipitation and Quantitative PCR
Chromatin immunoprecipitation (ChIP) and quantitative PCR
(qPCR) were essentially performed as previously described
[71,72]. Primary antibodies AP2a(C-18):sc-184 (Santa Cruz
Biotechnologies) and anti-Pol II (Abcam, ab5095) were utilized
for the immunoprecipitation reactions. qPCRs were performed
with a Roche LightCycler 480 machine utilizing the Roche Light
Cycler SYBR Green Master Mix (Roche) according to the
manufacturer’s instructions. Primers were designed using the
primer 3 software [73].
Supporting Information
Figure S1 Analysis of AP2a binding to PBM DNA
sequences.
(TIF)
Figure S2 AP2a weight matrix as computed from
SELEX data.
(TIF)
Figure S3 Correlation of AP-2a binding scores as
predicted in silico (A) or determined using a PBM (B).
(TIF)
Figure S4 Additional network diagrams illustrating
prominent molecular relationships of the products of
AP2a-bound genes.
(TIF)
Figure S5 Functional validation in HEPG2 cells of AP-2a
target genes, as selected from PBM and weight matrix-
based predictions.
(TIF)
Table S1 Potential AP2a target sequences identified by
PBM using the AP2a purified protein. Sequences bound by
recombinant AP2a protein on hu6k microarray (P,0.05).
(PDF)
Table S2 Network associated functions generated by
IPA using sequences ID from table S1.
(PDF)
Table S3 Human genomic sequences cloned into the
eGFP reporter plasmid for experimental validation.
Highest AP2a weight matrix score are indicated in the table and
corresponding sequences are underlined.
(PDF)
Table S4 Potential AP2a target sequences identified by
PBM using the nuclear protein extract from normal
breast tissues. Sequences bound by AP2a protein in nuclear
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cell extract from healthy breast tissues on hu6k microarray
(P,0.05).
(XLS)
Table S5 Potential AP2a target sequences identified by
PBM using the nuclear protein extract from breast
tumor tissues. Sequences bound by AP2a protein in nuclear
cell extract from cancer breast tissues on hu6k microarray
(P,0.05).
(PDF)
Table S6 Analysis of the first 50 sequences found to be
bound by AP2a in recombinant AP2 extract and in
normal and cancer tissues extracts. Scores were defined by
Weight Matrix Prediction Algorithms for AP2a and p53. For
AP2a, scores ,30 were defined as low binding sites. For p53,
scores ,50 were defined as low binding sites.
(PDF)
Table S7 Network associated with disease generated by
IPA using the 149 genes differentially regulated in
normal versus cancer tissues nuclear extracts.
(XLS)
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